540
+0.37%
Close of 9 Nov 2026, in JPY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Astena Holdings Co
Its shares trade on Tokyo Stock Exchange under the ticker 8095.T. It has been listed since 2 July 1963. In the fiscal year to 30 November 2025, it reported revenue of ¥62.74bn and net income of ¥2.19bn. At that date it held total assets of ¥75.44bn and shareholders' equity of ¥27.08bn.
Astena Holdings Co., Ltd. engages in the developing, supplying and wholesale of pharmaceuticals, cosmetics, chemicals, and food products. The company is headquartered in Chuo-Ku, Tokyo-To. The firm operates through four business segments. The Fine Chemicals segment is engaged in manufacture and sale of pharmaceutical raw materials and pharmaceuticals. The Medical segment is engaged in the manufacturing and sales of pharmaceutical products. The HBC and Food segment is engaged in the manufacture and sale of cosmetic raw materials, functional food raw materials, general use medicines and related products, as well as cosmetics. The Industrial Chemicals segment manufactures and sells chemicals for electronic industries, surface treatment chemicals, chemical products, surface treatment chemical raw materials, as well as to printed circuit board and other manufacturing plants. The other businesses include consulting services and others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 2 Jul 1963
- Employees
- 1,383
- Website
- astena-hd.com ↗
Leadership
Pay as last reported
- Mr. Satoshi SetoguchiPresident, Representative Director, since 2017
- Mr. Minoru KadokuraManaging Executive Officer, President of Subsidiary
- Mr. Makoto FujiwaraManaging Executive Officer, President of Subsidiary
- Mr. Katsumi FuruhashiManaging Executive Officer, President of Subsidiary, since 2016
- Mr. Eisuke FutagamiManaging Executive Officer, Chairman and President of Subsidiaries
- Mr. Hirotoshi NaruseManaging Executive Officer, Manager of FC/Pharmaceutical Business Structural Reform Office, since 2025
- Ms. Utano ShimizuManaging Executive Officer, President of Subsidiary
- Mr. Naoki EnomotoExecutive Officer
- Mr. Satoshi KawashimaExecutive Officer, Manager of Internal Audit Office
- Mr. Keitaro IwakiDirector, since 2007
- Mr. Takeshi KawanoDirector
- Ms. Mikiko NagaiIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Astena Holdings employs 1,383 full-time employees in Japan.
- The Fine Chemicals segment supplies pharmaceutical raw materials in Japan.
- The Medical segment manufactures and sells pharmaceutical products domestically.
Weaknesses
- The company operates in the Health Care sector with limited international presence.
- The HBC and Food segment focuses on domestic markets for cosmetics and functional foods.
- The Industrial Chemicals segment serves electronic industry clients in Japan only.
Opportunities
- Expanding the Fine Chemicals segment into international markets for pharmaceutical raw materials.
- Growing demand for pharmaceutical products in the Japanese Medical segment.
- Increasing the HBC and Food segment's export of cosmetic raw materials.
Threats
- Competition from global pharmaceutical companies in Japan.
- Regulatory changes affecting the Japanese pharmaceutical industry.
- Economic downturns impacting the Japanese consumer market.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.